Reflecting the limited therapeutic effects of various single agents which have been tested in previous and ongoing studies related to NASH and NASH-HCC, with most recent clinical trial in failure of selonsertib (SEL; GS-4997), apoptosis signal-regulating kinase 1 (ASK1) inhibitor, it might be assumed that the analysis for the synergy effects of multidrug administration against NASH and NASH-HCC will be planned in the near future. Here, MAP3K5 is linked to hepatocellular carcinoma.